Etherna
About us

We are an RNA technology company, with over 30 years’ experience, offering professional partnerships to pharma and biotech with an emerging or established interest in RNA therapeutics. Our expert team supports start-up, early stage, and late stage projects using our proprietary platforms across RNA chemistry, LNP formulation, and Process Technology, to drive new pipeline development or resolve manufacturing challenges for our partners.

Who we are
image of two people
Etherna
Our technology platforms
Our comprehensive range of platforms provide a one-stop solution for your complete mRNA drug development needs
scientist viewing sample
LNP formulation

Our innovative proprietary LNP platforms are tailored for specific routes of administration, intravenous (IV), intra-tumoral (IT) and intramuscular (IM), allowing better targeted biodistribution. Studies have demonstrated substantial mRNA payload distribution to target tissue.

Learn more about our LNP formulation
mRNA chemistry

Our proprietary mRNA chemistry platform technology enable sequence engineering of mRNA constructs to ensure optimal mRNA translation efficiency and maximal mRNA stability. Sequence engineering can be tuned to enable immune silent or immune-stimulatory mRNA, in addition, constructs can be optimized for improved tissue specific expression.

Learn more about our mRNA chemistry
person in laboratory
Etherna
Latest news
May 21, 2024
etherna and Hasselt University announce autoimmune mRNA therapeutics research collaboration
April 16, 2024
Shelly West joins etherna as Business Development Director US
February 13, 2024
Landmark peer-reviewed paper shows etherna LNP formulations for intramuscular injection combine the induction of strong immune responses with significantly reduced local reactogenicity and systemic distribution
Etherna
Partner with us
TECHNOLOGY PARTNERING

Differentiated mRNA capabilities and innovative, differentiated lipid formulations that enable targeted delivery and tailored biodistribution.

PRODUCT PARTNERING

The continuation of our pipeline products, from IV administered HPC16+ cancer treatment (clinically ready), to intra tumoral platform containing proprietary immune-activating mix and ex vivo activation of dendritic cells for oncology (phase 2 data available).

MANUFACTURING SERVICES

More than 30 years experience of manufacturing research grade RNA, and more than 5 years of GMP RNA production experience in our cGMP accredited RNA production facility in Niel, Belgium.

Etherna
Why choose to work with us
icon
Pioneering expertise
icon
Integrated offering
icon
Flexible partnership
icon
Europe GMP facilities
Contact us to discuss your RNA partnering needs
Etherna
Shareholders